Nerve conduction within the mammalian central nervous system is made efficient by oligodendrocyte-derived myelin. Historically, thyroid hormones have a well described role in regulating oligodendrocyte differentiation and myelination during development; however, it remains unclear which thyroid hormone receptors are required to drive these effects. This is a question with clinical relevance since nonspecific thyroid receptor stimulation can produce deleterious side-effects. Here we report that GC-1, a thyromimetic with selective thyroid receptor b action and a potentially limited side-effect profile, promotes in vitro oligodendrogenesis from both rodent and human oligodendrocyte progenitor cells. In addition, we used in vivo genetic fate tracing of oligodendrocyte progenitor cells via PDGFaR-CreER;Rosa26-eYFP double-transgenic mice to examine the effect of GC-1 on cellular fate and find that treatment with GC-1 during developmental myelination promotes oligodendrogenesis within the corpus callosum, occipital cortex and optic nerve. GC-1 was also observed to enhance the expression of the myelin proteins MBP, CNP and MAG within the same regions. These results indicate that a b receptor selective thyromimetic can enhance oligodendrocyte differentiation in vitro and during developmental myelination in vivo and warrants further study as a therapeutic agent for demyelinating models.
Introduction
T hyroid hormones (THs) play a critical role in developmental oligodendrogenesis and myelination. Acting through nuclear hormone receptors, THs have been shown to promote the expression of a number of oligodendrocyte specific genes including myelin basic protein (MBP), myelinassociated glycoprotein (MAG), proteolipid protein (PLP), and cyclic nucleotide 3 0 -phosphodiesterase (CNP) (Farsetti et al., 1991 (Farsetti et al., , 1992 Rodriguez-Pena et al., 1993; Tosic et al., 1992) . In vivo, numerous studies of hypo-and hyperthyroid animals as well as genetically modified rodents have provided clear evidence that THs regulate oligodendrocyte differentiation and maturation (Bernal, 2002 (Bernal, , 2007 Darras, 2008; Dugas et al., 2012; O'Shea and Williams, 2002; Zoeller and Rovet, 2004) . Despite unequivocal evidence of the important role played by THs in myelination, we do not yet clearly understand which thyroid hormone receptors (THRs) are required to mediate these effects (Baas et al., 1997; Bernal, 2002 Bernal, , 2007 Darras, 2008; O'Shea and Williams, 2002; Zoeller and Rovet, 2004) . Moreover, long-term nonspecific THR activation can cause serious side effects that limit the translational potential of THs for the treatment of myelin disorders occurring both developmentally (for example cerebral palsy) and in the adult central nervous system (CNS) (multiple sclerosis, monophasic optic neuritis and transverse myelitis). We investigated the potential for a b THR selective thyromimetic, GC-1, to stimulate oligodendrocyte differentiation in rodent and human cultures in vitro and in vivo during development in the mouse. There are two circulating THs: thyroxine (T4) and triiodothyronine (T3). T4 is the principal product of the thyroid gland and the most abundant circulating TH. However, most classic TH actions are believed to be mediated by T3 (Yen, 2001) . T4 is converted to T3 by deiodinases within target organs.
TH actions are mediated through nuclear hormone receptors that are encoded by two different genes. The THRa gene encodes two isoforms (a1 and a2) while an additional four isoforms are encoded by the b gene (b1-4) (Tagami et al., 2010; Williams, 2000; Yen, 2001) . In general, THRas regulate cardiac rate and contractility (Gloss et al., 2001; Johansson et al., 1998) while THRbs control inner-ear and retina development (Rusch et al., 2001) , cholesterol homeostasis (Gullberg et al., 2002) , lipoprotein metabolism (Tancevski et al., 2009) , and TH levels (Weiss et al., 1997) .
Potential side effects mediated by excessive, nonselective THR stimulation are akin to hyperthyroidism and include tachycardia, arrhythmia, decreased mineral bone density and muscle wasting (Baxter et al., 2001; Johansson et al., 1998; Mansen et al., 2010) . Selective modulation of the b receptor has been shown to circumvent many of these undesirable effects, thus widening the safety margin between therapeutic and harmful effects (Borngraeber et al., 2003; Freitas et al., 2003; Grover et al., 2004; Miyabara et al., 2005; Scanlan, 2010; Trost et al., 2000) . However, it is not known whether THRb1 activation is sufficient to promote oligodendrogenesis.
In vitro studies indicate that oligodendrocyte progenitor cells (OPCs) express both THRa and THRb1 and expression of the latter increases with oligodendrocyte maturation (Barres et al., 1994; Gao et al., 1998) . Overexpression of THRb1 in mouse OPCs was found to accelerate TH-induced differentiation (Billon et al., 2001) . Furthermore, THRb1 has been shown to be a better transactivator of the MBP TRE versus THRa1 (Jeannin et al., 1998) . Taken together, these studies suggest an important role for THRb1 in OL maturation.
Here we report that GC-1, a thyromimetic with selective THRb action (Chiellini et al., 1998; Manzano et al., 2003; Trost et al., 2000) , promotes oligodendrogenesis from both rodent and human OPCs in vitro. Using in vivo genetic fate tracing of OPCs, we found that GC-1 enhances oligodendrogenesis during development and increases production of the myelin proteins MBP, CNP and MAG. These results indicate that thyromimetics selective for the b receptor can enhance OL differentiation and promote myelination while limiting the potential for serious side effects elicited by nonspecific THR activation.
Materials and Methods

Animals
PLP-enhanced green fluorescent protein (eGFP) mice were a kind gift from Dr. Wendy Macklin (Mallon et al., 2002) . NG2-DsRed BAC transgenic mice and PDGFaR-CreER mice were generated as described previously (Kang et al., 2010; Ziskin et al., 2007) . Rosa26-eYFP mice were purchased from the Jackson Laboratory. C57BL/6 mice were purchased from National Cancer Institute, Frederick. Timed pregnant Sprague Dawley rats were purchased from Charles River. The care and treatment of animals in all procedures strictly followed the NIH Guide for the Care and Use of Laboratory Animals and the Johns Hopkins University IACUC. Mice and rats were housed at standard temperature (21 C) and in a light controlled environment with ad libitum access to the food and water.
In Vitro Studies
Isolation and Culture of Murine DsRed 1 OPCs NG2-DsRed and PLP-eGFP mice were crossbred to create double transgenics. Postnatal day (P) 2-6 mice were sacrificed and the cerebrum rapidly dissected in ice-cold Hank's Balanced Salt Solution (HBSS). Following removal of the meninges, tissue was diced with a razor blade prior to cellular dissociation using the MACS V R Neural Dissociation Kit (Miltenyi Biotec) according to the manufacturer's instructions. DsRed expressing cells were fluorescence-activated cell sorted (FACS) using a MoFlo MLS high speed cell sorter (Beckman coulter) with Summit version 4.3 software. Cell suspension preparation and FACS was completed within 2-3 h.
Sorted cells were plated onto either poly-L-lysine (PLL; 10 lg/mL, Sigma) coated glass coverslips (for immunocytochemistry) or 96 well, black-walled plates (Greiner Bio-One; for reporter assay) and cultured in Sato media (modified from (Bottenstein and Sato, 1979) Dulbecco's Modified Eagle Medium containing B27, glutamine, penicillin/streptomycin, sodium pyruvate, (all from Life Technologies), 100 lg/mL apo-transferrin, 100 lg/mL BSA, 60 ng/mL progesterone, 16 lg/mL putrescine, 40 ng/mL sodium selenite, 50 lg/mL insulin, 5 lg/mL n-acetyl cysteine, 10 ng/mL biotin, 50 ng/mL hydrocortisone (all from Sigma) and trace elements B (Cellgro)) supplemented with 10 ng/mL recombinant human platelet derived growth factor-AA (PDGF-AA, PeproTech). After 4 days in vitro, cells were either maintained in PDGF (proliferation media) or switched to Sato media containing T3 (Sigma) or GC-1 (generous gift from Dr. Thomas Scanlan (Chiellini et al., 1998) ) for a further 4 days. Media changes were made every other day. For proliferation studies, 10 lM 5-bromo-2 0 -deoxyuridine (BrdU, Sigma) was added to cultures at the time they were switched to differentiation media and 24 h prior to fixation.
Immunocytochemistry and Microscopy
Cells were fixed in 4% paraformaldehyde, rinsed and then permeabilized in phosphate buffered saline (PBS) containing 5% normal goat serum (NGS) and 0.4% Triton-X100 for 1 h at room temperature (RT). For BrdU immunostaining, cells were preincubated in 2 N HCl at RT for 20 min, followed by neutralization with 0.1 M sodium borate buffer (pH 8.5) prior to immunolabeling. Cells were then incubated overnight at 4 C in PBS containing 3% NGS, 0.1% Triton X-100 and primary antibody as follows; guinea pig anti-NG2 (1:300); rabbit anti-platelet derived growth factor a receptor (PDGFaR) (1:600, both courtesy of Dr. Bill Stallcup); rabbit anti-Olig2 (1:1,000, Millipore); mouse anti-MBP (smi99, 1:1,000, Covance); rat anti-BrdU (1:100, Accurate); mouse anti-CNP (1:750, Millipore) and chicken anti-GFP (1:1,000, AbCam). The next day, cells were rinsed and incubated for 1 h at RT with species-specific secondary antibodies directly conjugated to Alexa fluorophores (1:1,000, Life Technologies). Coverslips were mounted in ProLongV R Gold anti-fade reagent with 4 0 ,6-diamidino-2-phenylindole (DAPI) and visualized on a Zeiss Axio Observer Z1 epifluorescence microscope. Images were captured and processed using AxioVision 4.8 software. Cell counts were made at 2003 from three fields of view per condition in three separate experiments.
Quantification of Murine In Vitro Oligodendrogenesis
Quantification of eGFP and MBP immunoreactivity was performed using In-cell Western analysis (Odyssey Infrared Imaging System; Li-Cor Biosciences) according to the manufacturer's guidelines. Cells cultured in 96-well plates were fixed and prepared for immunocytochemistry with either anti-GFP or anti-MBP as indicated above. Species-specific secondary antibodies conjugated to 800CW infrared dye (1:5,000, LiCor Biosciences) were incubated in PBS containing 3% NGS and 0.1% Tween-20 along with the nuclear stain Syto60 (1:10,000, Life Technologies) for 1 h at RT. After washing, plates were scanned simultaneously at 700 and 800 nm using the Odyssey Infrared Imaging System. Isolation and Culture of Rat OPCs P6 Sprague Dawley rat pups were sacrificed and cortices rapidly dissected in ice-cold HBSS. Tissue was mechanically diced prior to cellular dissociation using the MACS V R Neural Dissociation Kit (Miltenyi Biotec) as described above. OPCs were selected by immunomagnetic bead selection according to the manufacturer's instructions using mouse monoclonal anti-A2B5 IgM antibodies conjugated to microbeads (Miltenyi Biotec) . The A2B5 1 cell fraction was resuspended in Sato media and cultured as described for the murine OPCs above. Rat OPCs were proliferated in 10 ng/mL PDGF for 4 days prior to differentiation for an additional 4-8 days.
Quantitative PCR Rat cells were lysed directly in 6-well plates using 600 lL of buffer RLT (Qiagen) and immediately homogenized in QIAshredder columns (Qiagen). Homogenized lysates were stored at 280 C until the conclusion of each trial and then processed simultaneously with the RNeasy plus mini kit (Qiagen) according to supplementary protocol RY26 (Qiagen). Genomic DNA was removed using gDNA elimination columns included with the kit. Samples of total RNA (1,600 ng) were reverse transcribed in a 40 lL reaction volume with the NCode VILO cDNA synthesis kit (Life Technologies). The cDNA samples were diluted to 10 ng/lL in water and 5-50 ng of diluted cDNA was used for qPCR. Reactions were performed in triplicate using a 20 lL volume, 400 nM primer, SensiMix SYBR master mix (Bioline), and CFX384 Touch or iCycler iQ RealTime PCR Detection Systems (Bio-Rad). Cycling conditions were as follows: 10-min initial denature, followed by 40 cycles 
Western Blot Analysis of Rat OPCs
Rat cells were lysed in radio immunoprecipitation assay (RIPA) buffer (Boston BioProducts) and protein abundance quantified using the Bradford assay (Bio-Rad). Equal amounts of protein were denatured in Laemmli's SDS sample buffer containing b-mercaptoethanol (Boston BioProducts) prior to separation on 12% polyacrylamide gels (Critereon, TGX, Bio-Red) by electrophoresis. For detection of MAG, protein samples were prepared in a nondenaturing Laemli's sample buffer (Boston BioProducts). Samples were then transferred to PVDF membrane. Membranes were blocked in 0.1% Tween-20 TBS containing 5% nonfat milk for 1 h prior to incubation with primary antibodies. Primary antibodies were diluted in the same solution as follows; anti-MBP (clone smi99; Covance) 1:1,000; anti-THRb1 (clone J52; Santa Cruz) 1:300; and anti-b-actin (clone 20-33; Sigma) 1:5,000. Anti-mouse or anti-rabbit secondary antibodies conjugated to IRDyeV R 680 or 800 were incubated for 1 h prior to scanning the membrane on a LI-COR OdysseyV R imager. Images were analyzed using the OdysseyV R infrared imaging system application software version 3.0. Protein expression was normalized to b-actin.
Isolation and Culture of Human OPCs
OPCs were isolated from grey matter tissue surgically resected from patients with intractable epilepsy. Tissue procurement and use was conducted in accordance with the Johns Hopkins Institutional Review Board (study number NA_00040083). Patients were aged 2-19 years. Brain resections were taken from nonpathological tissue surrounding the epileptic focus. Using a dissecting microscope, meninges were removed and grey matter dissected in chilled HBSS. In preliminary experiments, we achieved a lower OPC yield from white matter tissue (most likely due to the additional processing required for myelin removal). Tissue was diced with a razor blade prior to cellular dissociation using the MACS V R neural dissociation kit (Miltenyi Biotec). Cells were selected based on expression of a known human OPC antigen, A2B5 (Miron et al., 2007; Sim et al., 2008; Wilson et al., 2003) . A2B5 1 cells were collected using magnetic cell sorting (MACS) according to the manufacturer's instructions (Miltenyi Biotec) and plated onto PLL (10 lg/mL, Sigma) coated glass coverslips. Sato media (as described above) supplemented with 10 ng/mL PDGF was used to proliferate the OPCs for the first 7 days in culture. After this time, PDGF was either withdrawn or replaced with 20 nM T3 or GC-1. Seven days later, cells were fixed and immunostained as described above.
In Vivo Studies GC-1 Treatment P7 C57BL/6 mice were treated daily with 3 lg GC-1 or an equal volume of vehicle by intraperitoneal injection daily until the time of sacrifice 1 week later.
Western Blot Analysis
For THRb1 studies, P0, P7, P14, and 8-week-old C57BL/6 mice were sacrificed, perfused transcardially with chilled PBS and the brains dissected. For myelin protein studies following GC-1 treatment, P14 mice were perfused with chilled PBS and the optic nerves and brains collected. The corpus callosum and occipital cortex were dissected with the aid of a dissecting microscope. Nuclear and cytoplasmic extracts were prepared from tissue using NU-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to manufacturer's instructions. Immunoblotting was conducted as described above. THRb1 levels were assessed in nuclear protein fractions using anti-THRb1 (clone J52; Santa Cruz) 1:300. The identity of the THRb1-specific band was verified by comparison with a positive control (Supporting Information Fig. S2 ). Myelin proteins were assessed using cytoplasmic protein fractions and using the same immunoblotting conditions as described for the in vitro experiments above.
In Vivo Fate Tracing of OPCs 4-hydroxytamoxifen (4-HT, Sigma H7904) was prepared as described previously (Badea et al., 2003) . PDGFaR-CreER;-Rosa26-eYFP mice were injected with a total of 0.3 mg over 3 days from P7-P10. Starting on P7, mice were administered 3 lg GC-1 or an equal volume of vehicle by intraperitoneal injection daily until the time of sacrifice 1 week later. Mice were deeply anesthetized with sodium pentobarbital (100 mg/ kg b.w.) and perfused trancardially with chilled PBS followed by 4% paraformaldehyde. Brains and optic nerves were dissected, postfixed overnight and cryoprotected in 30% sucrose for approximately 48 h prior to freezing. Tissue was sectioned on a cryostat (20 lm) and mounted onto glass slides (Superfrost Plus; Fisher). For adenomatous polyposis coli (APC) immunostaining, tissue was pretreated in LAB solution (Polysciences) for 10 min before blocking. Sections were blocked and permeabilized in PBS containing 5% NGS and 0.4% Triton-X for 1 h at RT and then incubated overnight at 4 C in PBS containing 3% NGS, 0.1% Triton X-100 and primary antibody as follows; mouse anti-APC (clone CC-1, 1:50, Calbiochem); rabbit anti-PDGFaR (as above) and chicken anti-GFP (as above). Species-specific secondary antibodies directly conjugated to Alexa fluorophores (1:1,000) were used to visualize immunostaining. Sections were incubated in secondary antibodies for 1 h at RT prior to mounting in anti-fade reagent with DAPI.
Mounted slides were imaged using a Zeiss Axio Observer Z1 epifluorescence microscope and Axiovision software with the appropriate excitation and emission filters. A total of three to five sections were examined per mouse, and three to five mice were analyzed per group. Areas were chosen randomly within the indicated regions of brain or optic nerve.
Statistical Analyses
Data are expressed as mean 6 standard error of the mean. Unpaired Student's t-tests (two-tailed) were used to distinguish significant differences in reporter OPC immunoreactivity in vitro and lineage fate in vivo. All other in vitro studies were analyzed using One-way ANOVA followed by Dunnett's multiple comparison test. These statistical tests were conducted using GraphPad Prism 5.03 (GraphPad Prism Software). P values of < 0.05 were considered significant.
Results
Generation of a Novel In Vitro System to Monitor Oligodendrogenesis
We wished to develop an in vitro technique that would allow us to monitor oligodendrogenesis in a sensitive and quantitative manner. To generate mice that would allow isolation of OPCs based on their expression of NG2 and then track their capacity to differentiate into mature OLs, we crossed PLPeGFP transgenic mice (Mallon et al., 2002) to NG2-DsRed BAC transgenics (Ziskin et al., 2007) and used FACS to select all DsRed 1 cells from the brains of mice aged between P2 and P6 (Fig. 1A) . We did not exclude cells that were DsRed 1 /eGFP 1 since activity from the DM20 promoter of the PLP-eGFP mouse can induce limited eGFP expression in progenitor cells (Mallon et al., 2002) . Immunocytochemical characterization of DsRed 1 -selected cells 8 days post-isolation revealed a high percentage of PDGFaR (77%) and NG2 (94%) immunoreactive cells when maintained in media supplemented with the mitogen, PDGF (Fig. 1B,C) . Under these conditions, there was no detectable expression of MBP and very few (1.5%) eGFP 1 cells.
Although there was no change in the expression of Olig2 (a pan OL lineage marker) following treatment with T3 (81 vs. 86%), there was a significant decrease in expression of PDGFaR and NG2, a marked increase in MBP expression and an increase in eGFP 1 cells (Fig. 1B,C) . These results
show that TH-stimulated differentiation of isolated DsRed
1
OPCs is faithfully reported by increased expression of eGFP in OLs. Once it was established that DsRed
/eGFP
1 OPCs function as reporter cells for OL differentiation, we developed a quantitative in vitro assay to screen for OL generation. In DsRed 1 cells isolated from the brains of NG2-DsRed;PLP-eGFP transgenic mice, OL differentiation results in increased eGFP expression and this increase can be detected and quantified using an in-cell western approach (Fig. 2) . Specifically, an antibody against eGFP was used to immunolabel differentiated cells which were then detected using an infrared secondary and the LI-COR Odyssey system. This facilitated a quantitative assessment of oligodendrogenesis in a 96-well format using infrared fluorescence imaging and quantification. To verify the fidelity of this method, we compared it with two additional methods of quantification; manual cell counts of eGFP 1 cells and infrared detection of MBP immunolabeled cells. Comparable results were obtained when estimating oligodendrogenesis under three different conditions (1PDGF, T3 1PDGF and T3-PDGF) using these techniques (Fig. 2) .
GC-1 Promotes Oligodendrogenesis in Murine Cells In Vitro
To determine if GC-1, a THRb selective agonist, promotes oligodendrogenesis, DsRed 1 cells were cultured in the presence of PDGF for 4 days. Withdrawal of PDGF for an additional 4 days increased eGFP expression, but the effect was not significant (Fig. 3A,B) . Exposure to 10 and 20 nM GC-1 and 30 nM T3 induced a two-fold increase in eGFP when compared with PDGF withdrawal alone. At a concentration of 30 nM, GC-1 produced an approximately three-fold increase in eGFP, which was significantly greater than PDGF FIGURE 3: GC-1 promotes oligodendrogenesis without significantly decreasing mitogen-induced proliferation. DsRed 1 OPCs were cultured for 4 days in media supplemented with 10 ng/mL PDGF followed by an additional 4 days under the following conditions; PDGF, PDGF withdrawal, PDGF withdrawal and 30 nM T3, PDGF withdrawal and 10, 20 or 30 nM GC-1. (A) Native eGFP expression in OPCs under indicated conditions. (B) 30 nM GC-1 significantly increases oligodendrogenesis when compared with PDGF withdrawal alone. n 3, **P < 0.005, One-way ANOVA, Dunnett's multiple comparison test. (C) OPC proliferation in a 24 h period is reduced by withdrawal of PDGF. There is no further decrease in proliferation mediated by addition of either T3 or GC-1. In the presence of PDGF, neither T3 nor GC-1 has a significant effect on OPC proliferation n 5 3 **P < 0.005, One-way ANOVA, Dunnett's multiple comparison test. (D) Representative images of BrdU (magenta) incorporation into the nuclei (DAPI: blue) of OPCs cultured under the indicated conditions. Scale bar represents 50 lm.
withdrawal alone, showing that GC-1 can effectively promote murine OL differentiation in vitro.
To determine the effect of GC-1 on OPC proliferation, we measured BrdU incorporation during a 24 h time period (Fig. 3C,D) . As expected, withdrawal of the mitogen, PDGF, significantly decreased proliferation from 36% to 11% (n 5 3, P < 0.005, One-way ANOVA). However, an additional significant decrease in proliferation was not observed upon exposure to T3 or GC-1 at doses up to 30 nM. In the presence of PDGF and either T3 or GC-1, we noted a trend, but no significant decrease in OPC proliferation when compared with PDGF alone.
THRb1 is Upregulated in Response to GC-1-Mediated OL Differentiation A2B5
1 OPCs derived from rat cortices were used to investigate if GC-1-mediated differentiation was accompanied by a change in the expression of THRb1. As for murine cultures, 30 nM T3 and GC-1 were both observed to induce oligodendrogenesis in rat cells as indicated by shifts in PDGFaR and MBP immunostaining (Fig. 4A) . Western blot analyses also revealed increased production of the myelin proteins CNP, MBP and MAG in T3 and GC-1 treated cultures (Fig. 4B) . Neither T3 nor GC-1 was found to effect cell survival in vitro (Supporting Information Fig. S1 ). Using quantitative PCR, we determined that, when compared with PDGF withdrawal, no significant changes in THRa1 expression were observed post-differentiation (Fig. 4C) . In contrast, both T3 and GC-1 induced an increase in THRb1 expression at days 4 and 8 post-differentiation that was significantly above PDGF withdrawal (Fig. 4D) . Moreover, the observed increase at day 8 with GC-1 was significantly greater than T3.
GC-1 Promotes Oligodendrogenesis from Human Cells In Vitro
To determine if GC-1 is able to facilitate OL differentiation not only from rodent, but also from human cells, we isolated OPCs from human cerebral tissue. Tissue was derived from surgically resected grey matter tissue taken from patients with intractable epilepsy (see methods). Cells isolated using A2B5 immunoselection and maintained under proliferation conditions (1PDGF) for 2 weeks, were found to be NG2 1 (66%) GFAP 1 19%) and CNP 1 (15%) (Fig. 5) . As previously reported in the literature, we found that T3 promoted human CNP 1 OL differentiation (Othman et al., 2011; Wilson et al., 2003) . Treatment with GC-1 (20 nM) induced an increase (from 15 to 35%) in the number of CNP 1 human OLs similar to that of T3 treatment and significantly greater than that of PDGF withdrawal alone (15-19%, n 5 3, P < 0.05, One-way ANOVA).
THRb1, the Cellular Target of GC-1, is Expressed During Myelination in the Mouse Brain
Since GC-1 is a selective agonist for THRb1, we evaluated expression of this receptor during development in the mouse brain. We found that THRb1 expression peaked at P7-P14, just prior to and during accumulation of the myelin protein MBP (Fig. 6) . Notably, by 8 weeks, when myelination is mostly complete (Baumann and Pham-Dinh, 2001; Foran and Peterson, 1992) , THRb1 levels were diminished (8% of P7 levels, Fig. 5 ). These data indicate that THRb1 is developmentally regulated in a manner that corresponds with onset of MBP production.
GC-1 Enhances Oligodendrogenesis During Myelination
To determine if GC-1 enhances production of OLs in vivo during a critical myelination period (P7-P14), we made use of PDGFaR-CreER transgenic mice (Kang et al., 2010) to trace the fate of OPCs following GC-1 treatment. After crossing to Rosa26-eYFP reporter mice, we induced recombination of the reporter cassette and expression of eYFP within PDGFaR 1 cells. Starting at P7, we treated mice with 3 lg GC-1 or an equal volume of vehicle for 7 days until P14 when the mice were sacrificed. We examined the effect of GC-1 treatment in three regions of the CNS; the splenium of the corpus callosum, the occipital cortex and the optic nerve. Although OLs appear and myelinate different structures within the CNS at regulated times during development (Foran and Peterson, 1992) , we observed that GC-1 was able to significantly increase oligodendrogenesis in all three regions examined (Figs. 7-9) . In control mice, we observed that 39% of eYFP 1 cells in the splenium of the corpus callosum exhibited immunoreactivity to APC, a marker of mature OLs (Fig. 7C,E) . This number increased to 54% with GC-1 treatment. There was also a trend for decreased numbers of PDGFaR immunoreactive cells following GC-1 treatment (Fig. 7D,F) . Similar results were obtained in the occipital cortex (23% eYFP 1 APC 1 cells in controls versus 35% following GC-1 treatment, Fig. 8 ) and optic nerve (40% eYFP 1 APC 1 cells in controls versus 57% following GC-1 treatment, Fig. 9 ) indicating that GC-1 promotes oligodendrogenesis in vivo. We did not note a significant change in the diameter of optic nerve fibers between the two groups (the average diameter of optic nerves in the control groups was 260 6 46 lm and in the GC-1 treated groups was 270 6 20 lm).
GC-1 Increases Expression of the Myelin Proteins MBP, CNP, and MAG
Having observed an increase in numbers of newly generated OLs following GC-1 treatment from P7 to P14, we next wished to investigate if this effect was associated with an increase in myelin protein expression. By Western blot, we determined that GC-1 significantly increased the expression of MBP, CNP and MAG within the same three regions (corpus callosum, occipital cortex and optic nerve) where we observed enhanced OL numbers (Fig. 10) .
Discussion
THs have a number of potentially therapeutic effects, including oligodendrocyte differentiation and myelination (Barres et al., 1994; Billon et al., 2001; Calza et al., 2002; Dugas et al., 2012; Franco et al., 2008 ) that could be relevant to the treatment of demyelinating disorders. However, they also have the potential for serious side effects elicited by thyroid receptor signaling in non-CNS tissues. GC-1 is a thyromimetic selective for THRb (Baxter et al., 2001 ) that has been shown to mediate specific TH functions with significantly reduced risk for undesirable side effects, including cardiac stimulation mediated through THRa1 (Scanlan, 2010; Tancevski et al., 2009 ). While GC-1's effects on plasma cholesterol have been well described and have led to its consideration as a treatment for dyslipidemia (Tancevski et al., 2011), it is not yet understood whether selective stimulation of THRb1 is sufficient to drive oligodendrogenesis and myelination.
Here we show that GC-1 increases OL differentiation in both rodent and human derived OPC cultures. In vivo genetic fate tracing revealed that GC-1 also augments oligodendogenesis during development and this is associated with increased expression of myelin proteins.
Role of THRb1 in Oligodendrocyte Maturation and Myelination
Data presented herein indicate that THRb-selective agonism has the ability to effectively enhance both in vitro and in vivo oligodendrocyte differentiation. GC-1 has approximately the same affinity for THRb1 as T3 (70 pM versus 80 pM, respectively), but is selective for THRb1 over THRa1 (Chiellini et al., 1998) . Its selectivity rather than specificity for THRb1 means that we cannot rule out a contributing role of THRa in OPC differentiation. However, in our murine reporter assay (Fig. 3) , 30 nM GC-1 produced a significant increase in oligodendrogenesis that was not achieved with an equimolar dose of T3. This result suggests that selective THRb1 stimulation enhances differentiation.
OL differentiation can occur through a number of distinct pathways including mitogen-withdrawal and exposure to T3 (Barres et al., 1993 (Barres et al., , 1994 Dugas et al., 2010) . When OPCs are exposed to T3 in the presence of PDGF, they continue to proliferate and only differentiate following multiple rounds of cell division (Barres et al., 1994; Durand and Raff, 2000; Temple and Raff, 1986) . We found that like T3, GC-1 does not significantly affect OPC proliferation in the presence of PDGF (Fig. 3) . This is important from a therapeutic standpoint as inappropriate OL differentiation could deplete OPC numbers and hinder myelination. Similarly, we found that neither T3 nor GC-1 inhibited proliferation in vitro beyond the reduction produced by PDGF withdrawal itself.
THRb1 expression within the oligodendrocyte lineage has been somewhat controversial. While some groups (Baas et al., 1994a,b; Billon et al., 2001 Billon et al., , 2002 Bury et al., 2002) report expression in differentiated OLs but not OPCs, others have found THRb1 to be present in both cell types (Barres et al., 1994) . These discrepant findings may be explained by changes in the expression of THRb1 within OPCs that are dependent on the "age" of the cell. Barres et al. (Barres et al., 1994) found that OPCs derived from the P14 rat optic nerve were more sensitive to T3 than P1-derived OPCs that have presumably undergone fewer rounds of proliferation. This possibility is further supported by the observation THRb1 is found in greater abundance in OPCs isolated from P7 versus embryonic day 18 optic nerves and can progressively accumulate in vitro as the younger cells proliferate (Gao et al., 1998) . Together these studies support a role for THRb1 in the "cellular clock" mechanism that determines an OPC's propensity to differentiate. In agreement with these data, we find . A total of 632 YFP cells in the control and 778 cells in the GC-1 group were counted. Data are presented as mean 6 SEM, n 4/group, **P < 0.005 calculated using a two-tailed Student's t-test.
that THRb1 mRNA expression increases with time in vitro and that this effect is enhanced by exposure to either T3 or GC-1 (Fig. 4D) . T3 is known to regulate expression of THRb1, but not THRa1 (Baas et al., 1998; Liu et al., 2000) . Here we find that, like T3, exposure to GC-1 also increases the expression of THRb1 mRNA, but has no significant effect on THRa1 (Fig. 4C) .
Thyroid Hormone and Developmental Myelination
THs are known to play an important role in developmental myelination (Bernal, 2002; Besnard et al., 1994; Sarlieve et al., 2004) and treatment of neonatal rats with thyroxine (T4) has been shown to accelerate the appearance of OLs in the optic nerve (Barres et al., 1994) . Since GC-1 is known to cross the blood-brain barrier in rodents (Trost et al., 2000) (E) Representative images of occipital cortex from control and GC-1 treated mice immunolabeled for PDGFaR (red) and YFP (green). Scale bar represents 50 lm. Data are presented as mean 6 SEM, n 4/group, *P < 0.05 calculated using a two-tailed Student's t-test.
and THRb1 is expressed during development (Fig. 6) , we investigated whether treatment of neonate mice with GC-1 would augment OL differentiation. Using PDGFaR-CreER mice to trace the lineage of OPCs during a weeklong period from P7 to P14, we found that GC-1 enhanced the generation of OLs in the corpus callosum, the occipital cortex and the optic nerve. In agreement with Kang et al. (Kang et al., 2010) , we observed that PDGFaR1 cells remain committed to the oligodendrocyte lineage in the developing brain and did not deviate to either an astrocytic of neuronal fate (Supporting Information Fig. S3 ). Treatment with GC-1 did not change these outcomes.
While all three regions examined demonstrated a significant increase in oligodendrogenesis, the magnitude of the effect could be influenced by the intrinsic rate of myelination in each region. For example, in the optic nerve, myelination is known to proceed in a retinal-to-chiasmal direction following the appearance of MBP positive cells on P7 (Foran and Peterson, 1992) . In contrast, MBP positive cells are not observed in the corpus callosum until P9. Therefore, while P7-14 is a critical period for CNS myelination in general, the exact timing and rate of the process varies for each region. Thus, the magnitude of the effect mediated by GC-1 may also vary. It may be more difficult to drive myelination in a region that is not yet fully populated by OPCs or by axons receptive to myelination.
Since GC-1 promoted oligodendrogenesis during development, we next asked whether this change was associated . A total of 888 YFP cells in the vehicle and 637 cells in the GC-1 group were counted. Data are presented as mean 6 SEM, n 4/group, *P < 0.05 calculated using a two-tailed Student's t-test.
with an increase in myelin protein expression during the same time period. We found that the abundance of the myelin proteins MBP, CNP, and MAG were all significantly increased at P14 following treatment with GC-1 for 1 week prior. Although we have not investigated whether this effect is sustained, it does indicate the capacity for GC-1 to enhance myelination.
In summary, GC-1 treatment of both rodent and human derived OPCs was found to enhance oligodendrogenesis in vitro. Examining the lineage progression of PDGFaR 1 OPCs during development, we also observed a significant increase in OL generation in vivo. GC-1 may hold therapeutic potential for demyelinating disorders, but carry a lower risk of side effects compared to treatment with nonselective thyroid hormones. Data are presented as mean 6 SEM, n 4/group, ****P < 0.0001, ***P < 0.001, **P < 0.005, *P < 0.05 calculated using a two-tailed Student's t-test.
